Insulet (NASDAQ:PODD) Releases Quarterly Earnings Results, Beats Expectations By $0.40 EPS

Insulet (NASDAQ:PODD) posted its quarterly earnings results on Wednesday. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40, FiscalAI reports. The firm had revenue of $842.00 million for the quarter, compared to the consensus estimate of $832.63 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The company’s revenue for the quarter was up 19.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.24 earnings per share.

Here are the key takeaways from Insulet’s conference call:

• Third-quarter revenue rose 19.6% in constant currency to $842 million, supported by more than 20% growth in the global customer base. Adjusted operating margin expanded 490 basis points, and adjusted EPS increased 60% year over year.
• Insulet raised its 2026 outlook to the high end of its prior range, expecting 21%–22% constant-currency revenue growth and more than 30% adjusted EPS growth. It also expects approximately 150 basis points of adjusted operating margin expansion.
• Management expects 2027 revenue growth to be modestly below its prior mid-teens framework, with U.S. growth toward the lower end of its earlier range and international growth moderating meaningfully. The company cited tougher comparisons, less international price-mix benefit, new competition, and limited near-term contributions from launches.
• Insulet reported modest improvement in type 2 customer retention after changes to sampling, onboarding, sales incentives, and customer support. Its Omnipod Discover platform has been adopted by more than 35,000 users and 5,000 clinicians, though management said the impact of these efforts will build over time.
• The board approved a $1 billion increase to the share repurchase authorization, with $400 million planned for repurchases in the fourth quarter using cash on hand.

Insulet Trading Up 3.6%

Shares of PODD traded up $5.63 on Wednesday, hitting $160.49. 1,369,811 shares of the stock traded hands, compared to its average volume of 1,392,058. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88. The stock’s 50 day moving average is $141.21 and its two-hundred day moving average is $178.61. The firm has a market capitalization of $11.13 billion, a P/E ratio of 30.00, a P/E/G ratio of 1.21 and a beta of 1.06. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Wall Street Zen downgraded Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, October 24th. BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. JPMorgan Chase & Co. downgraded Insulet from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $275.00 to $152.00 in a research report on Thursday, August 6th. Leerink Partners lowered Insulet from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $247.00 to $145.00 in a research note on Thursday, August 6th. Finally, Wells Fargo & Company cut Insulet from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $255.00 to $144.00 in a research report on Wednesday, August 5th. Thirteen analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Insulet currently has a consensus rating of “Hold” and an average target price of $186.68.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted earnings of $1.99 per share, topping the $1.59 consensus estimate. Revenue increased 19.2% year over year to $842 million, also ahead of expectations, with reports citing stronger net income and margin expansion. Insulet Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company announced a $1 billion share buyback, which could support demand for shares and signals management’s willingness to return capital to investors. Insulet announces $1 billion equity buyback
• Neutral Sentiment: Insulet maintained its 2026 EPS outlook, providing continuity but no increase to the earnings forecast in the cited report. Insulet Q3 adjusted earnings, revenue rise; 2026 EPS outlook maintained

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.